
KLRS Stock Forecast & Price Target
KLRS Analyst Ratings
Bulls say
Kalaris Therapeutics is viewed positively because TH103’s Phase 1a data showed a differentiated anti-VEGF profile, with treatment-naïve wet AMD patients achieving a 9-letter BCVA gain, a 118 µm CST reduction, and 29% remaining rescue-free through six months after one dose. The manufacturing issue appears batch-specific and manageable, with the company resolving it, planning new clinical supply in 2Q27, and retaining enough cash through the readout, which reduces near-term execution risk despite the Phase 1b/2 data shifting to 2H27. Fundamentally, the bullish case is supported by a large $15B+ wet AMD market, TH103’s design for stronger VEGF inhibition and retinal retention, and a credible path to roughly $1.6B of global sales by 2040 with meaningful upside from broader retinal indications.
Bears say
Kalaris Therapeutics is a single-asset, clinical-stage company whose valuation depends almost entirely on TH103, leaving it highly exposed if the program fails to show sufficient efficacy, safety, or durability. The missed drug supply specifications pushed key Phase 1b/2 wet AMD data to 2H27 from 1H27, extending development risk while the company still has no commercial products and likely will need additional capital, creating dilution pressure amid ongoing net losses. Even if approved, TH103 would enter a crowded retinal market against established therapies like Eylea and Vabysmo, as well as emerging long-acting competitors, so weak differentiation or limited market acceptance could materially cap future revenue.
This aggregate rating is based on analysts' research of Kalaris Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
KLRS Analyst Forecast & Price Prediction
Start investing in KLRS
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Kalaris Therapeutics Inc (KLRS) Forecast
KLRS Analyst Forecast & Price Prediction
Start investing in KLRS
Order type
Buy in
Order amount
Est. shares
0 shares